Mobile

A prospective, randomized, double dummy, double blind, multi-center trial comparing the safety and efficacy of moxifloxacin 400 mg IV QD 24 hours to that of ertapenem 1.0 g IV QD 24 hours for 5 to 14 ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000874-56

A prospective, randomized, double dummy, double blind, multi-center trial comparing the safety and efficacy of moxifloxacin 400 mg IV QD 24 hours to that of ertapenem 1.0 g IV QD 24 hours for 5 to 14 days for the treatment of subjects with complicated intra-abdominal infections

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objective is to compare the safety and efficacy of intravenous moxifloxacin 400 mg administered once daily with those of intravenous ertapenem 1 g once a day in adult subjects with cIAI that require surgery and parenteral antibiotic therapy The primary efficacy variable for this trial is the clinical response 21 to 28 days after the completion of study drug therapy (Test of Cure visit).

Critère d'inclusion

  • Complicated intra-abdominal Infections

Liens